

Equity Analysis

The FDA announces that it is considering a delay in the approval of a new drug. Because the pharmaceutical company is well-known, this potential delay makes investors nervous and the company's stock begins to slip. Many investors begin selling at a record low. And your clients? With access to thorough commentary and analysis, they would learn that the new drug would account for less than one percent anticipated sales. Realizing that reaction to the FDA announcement is creating an artificially low price, cool and confident, your clients could reap the benefits of buying additional stock. Profitable business decisions require information not emotion.

The **Equity Analysis CustomWire** will supply real-time news reports, analysis, commentary and competitive business and financial information related to publicly-traded companies. Your customers will be the first to know if a big merger has been finalized, who's under the scrutiny of the SEC, the amortization plans of a business, mergers and acquisitions and other information related to equities.

Comtex's **Equity Analysis CustomWire** is comprised of high value analytical content of importance to investors. Contributing publishers include **MidnightTrader.com**, **JAGNotes.com** and **Briefing.com**. Company stock tickers are included in all stories.



Gut-feelings are not enough in today's volatile stock market. Give your clients the **Equity Analysis CustomWire**--the best and most complete information available to help them improve their bottom line.

Statistics

Daily Story Average:

- 40-80 stories per day, Monday-Friday

